vs
博士伦（BLCO）与STAAR SURGICAL CO（STAA）财务数据对比。点击上方公司名可切换其他公司
博士伦的季度营收约是STAAR SURGICAL CO的28.7倍（$1.4B vs $49.0M）。博士伦净利率更高（-4.1% vs -69.9%，领先65.8%）。博士伦同比增速更快（9.8% vs -35.8%）。博士伦自由现金流更多（$60.0M vs $-5.1M）。过去两年博士伦的营收复合增速更高（13.1% vs -18.4%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
STAAR Surgical是一家专注于眼科领域的全球医疗设备企业，主营可植入式隐形眼镜（ICL）及配套眼科手术耗材，为眼科医师提供微创视力矫正解决方案，产品覆盖北美、欧洲、亚太等全球主要市场。
BLCO vs STAA — 直观对比
营收规模更大
BLCO
是对方的28.7倍
$49.0M
营收增速更快
BLCO
高出45.6%
-35.8%
净利率更高
BLCO
高出65.8%
-69.9%
自由现金流更多
BLCO
多$65.1M
$-5.1M
两年增速更快
BLCO
近两年复合增速
-18.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $49.0M |
| 净利润 | $-58.0M | $-34.2M |
| 毛利率 | — | 64.7% |
| 营业利润率 | 8.0% | -57.0% |
| 净利率 | -4.1% | -69.9% |
| 营收同比 | 9.8% | -35.8% |
| 净利润同比 | -1833.3% | -541.3% |
| 每股收益（稀释后） | $-0.16 | $-0.69 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCOSTAA
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.3B | $49.0M | ||
| Q3 24 | $1.2B | $88.6M | ||
| Q2 24 | $1.2B | $99.0M | ||
| Q1 24 | $1.1B | $77.4M |
净利润BLCOSTAA
| Q4 25 | $-58.0M | — | ||
| Q3 25 | $-28.0M | — | ||
| Q2 25 | $-62.0M | — | ||
| Q1 25 | $-212.0M | — | ||
| Q4 24 | $-3.0M | $-34.2M | ||
| Q3 24 | $4.0M | $10.0M | ||
| Q2 24 | $-151.0M | $7.4M | ||
| Q1 24 | $-167.0M | $-3.3M |
毛利率BLCOSTAA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 64.7% | ||
| Q3 24 | — | 77.3% | ||
| Q2 24 | — | 79.2% | ||
| Q1 24 | — | 78.9% |
营业利润率BLCOSTAA
| Q4 25 | 8.0% | — | ||
| Q3 25 | 7.4% | — | ||
| Q2 25 | -0.9% | — | ||
| Q1 25 | -7.3% | — | ||
| Q4 24 | 6.8% | -57.0% | ||
| Q3 24 | 3.6% | 6.4% | ||
| Q2 24 | 2.1% | 12.0% | ||
| Q1 24 | 0.5% | -2.9% |
净利率BLCOSTAA
| Q4 25 | -4.1% | — | ||
| Q3 25 | -2.2% | — | ||
| Q2 25 | -4.9% | — | ||
| Q1 25 | -18.6% | — | ||
| Q4 24 | -0.2% | -69.9% | ||
| Q3 24 | 0.3% | 11.3% | ||
| Q2 24 | -12.4% | 7.5% | ||
| Q1 24 | -15.2% | -4.3% |
每股收益（稀释后）BLCOSTAA
| Q4 25 | $-0.16 | — | ||
| Q3 25 | $-0.08 | — | ||
| Q2 25 | $-0.18 | — | ||
| Q1 25 | $-0.60 | — | ||
| Q4 24 | $-0.00 | $-0.69 | ||
| Q3 24 | $0.01 | $0.20 | ||
| Q2 24 | $-0.43 | $0.15 | ||
| Q1 24 | $-0.48 | $-0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $230.5M |
| 总债务越低越好 | $5.0B | — |
| 股东权益账面价值 | $6.4B | $397.3M |
| 总资产 | $14.0B | $509.5M |
| 负债/权益比越低杠杆越低 | 0.78× | — |
8季度趋势，按日历期对齐
现金及短期投资BLCOSTAA
| Q4 25 | $383.0M | — | ||
| Q3 25 | $310.0M | — | ||
| Q2 25 | $266.0M | — | ||
| Q1 25 | $202.0M | — | ||
| Q4 24 | $305.0M | $230.5M | ||
| Q3 24 | $329.0M | $236.0M | ||
| Q2 24 | $285.0M | $235.2M | ||
| Q1 24 | $315.0M | $245.1M |
总债务BLCOSTAA
| Q4 25 | $5.0B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $4.8B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — | ||
| Q1 24 | $4.6B | — |
股东权益BLCOSTAA
| Q4 25 | $6.4B | — | ||
| Q3 25 | $6.4B | — | ||
| Q2 25 | $6.4B | — | ||
| Q1 25 | $6.4B | — | ||
| Q4 24 | $6.5B | $397.3M | ||
| Q3 24 | $6.6B | $428.1M | ||
| Q2 24 | $6.5B | $409.1M | ||
| Q1 24 | $6.7B | $392.8M |
总资产BLCOSTAA
| Q4 25 | $14.0B | — | ||
| Q3 25 | $13.8B | — | ||
| Q2 25 | $13.8B | — | ||
| Q1 25 | $13.4B | — | ||
| Q4 24 | $13.5B | $509.5M | ||
| Q3 24 | $13.5B | $537.6M | ||
| Q2 24 | $13.3B | $512.7M | ||
| Q1 24 | $13.3B | $492.5M |
负债/权益比BLCOSTAA
| Q4 25 | 0.78× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.76× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 0.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $642.0K |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $-5.1M |
| 自由现金流率自由现金流/营收 | 4.3% | -10.4% |
| 资本支出强度资本支出/营收 | 5.4% | 11.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-66.0M | $-7.7M |
8季度趋势，按日历期对齐
经营现金流BLCOSTAA
| Q4 25 | $136.0M | — | ||
| Q3 25 | $137.0M | — | ||
| Q2 25 | $35.0M | — | ||
| Q1 25 | $-25.0M | — | ||
| Q4 24 | $22.0M | $642.0K | ||
| Q3 24 | $154.0M | $3.8M | ||
| Q2 24 | $15.0M | $-10.4M | ||
| Q1 24 | $41.0M | $21.7M |
自由现金流BLCOSTAA
| Q4 25 | $60.0M | — | ||
| Q3 25 | $63.0M | — | ||
| Q2 25 | $-54.0M | — | ||
| Q1 25 | $-135.0M | — | ||
| Q4 24 | $-70.0M | $-5.1M | ||
| Q3 24 | $94.0M | $-2.4M | ||
| Q2 24 | $-57.0M | $-16.6M | ||
| Q1 24 | $-26.0M | $16.5M |
自由现金流率BLCOSTAA
| Q4 25 | 4.3% | — | ||
| Q3 25 | 4.9% | — | ||
| Q2 25 | -4.2% | — | ||
| Q1 25 | -11.9% | — | ||
| Q4 24 | -5.5% | -10.4% | ||
| Q3 24 | 7.9% | -2.7% | ||
| Q2 24 | -4.7% | -16.8% | ||
| Q1 24 | -2.4% | 21.3% |
资本支出强度BLCOSTAA
| Q4 25 | 5.4% | — | ||
| Q3 25 | 5.8% | — | ||
| Q2 25 | 7.0% | — | ||
| Q1 25 | 9.7% | — | ||
| Q4 24 | 7.2% | 11.7% | ||
| Q3 24 | 5.0% | 7.0% | ||
| Q2 24 | 5.9% | 6.3% | ||
| Q1 24 | 6.1% | 6.7% |
现金转化率BLCOSTAA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 38.50× | 0.38× | ||
| Q2 24 | — | -1.41× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
STAA
暂无分部数据
